Cibus Cuts Cash Burn Amid Regulatory Wins and Rice Commercial Push
Event summary
- Cibus' Q2 net cash usage declined 19% sequentially and 31% year-over-year to $20.9M.
- EU aligned with US on treating gene-edited crops without foreign DNA as conventionally bred.
- Rice herbicide tolerance traits testing underway with Interoc, targeting Latin American launch in 2028.
- Sustainable Ingredients program generating revenue with consumer-products partner.
- Craig Wichner appointed CEO to focus on converting technology platform into shareholder value.
The big picture
Cibus is positioning itself as a platform partner for sustainable agriculture, leveraging favorable regulatory shifts in both the US and EU. The company's focus on converting its technology into revenue streams comes amid heightened competition in agricultural biotech and increasing demand for reduced-input farming solutions. With $20M in cash reserves expected to last into early 2027, execution against commercial milestones will be critical.
What we're watching
- Commercial Execution
- Whether Cibus can sustain its cash burn reduction while advancing multiple crop programs.
- Regulatory Tailwinds
- How the EU's favorable regulatory shift will accelerate commercialization timelines.
- Partnership Strategy
- The pace at which Cibus can expand its multi-trait pipeline with seed company partners.
Related topics